Mylan (NASDAQ: MYL) announced that the U.S. Patent and Trademark Office (PTO) has instituted inter partes review (IPR) proceedings against ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Litigation Management Comments

Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceedings against Two Copaxone® 40 mg/mL Dosing PatentsAugust 25, 2015 2:59 PM UPDATE: Momenta Phama (MNTA) Whipsawed; Teva (TEVA) Capaxone Patents Under Scrutiny Said to be for Long-Acting Version - BloombergAugust 25, 2015 2:40 PM U.S. regulators will reconsider Teva's (TEVA) Copaxone patents - Bloomberg (MYL)August 25, 2015 2:38 PM